CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy

Clinical and Experimental Metastasis

Volumn 33, Issue 8, 2016, Pages 787-798

  Di Gennaro, P ^a   Gerlini, G ^a   Urso, C ^a   Sestini, S ^a   Brandani, P ^a   Pimpinelli, N ^b   Borgognoni, L ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Electrochemotherapy; ICD; Immunotherapy; Melanoma; TILs; Treg cells

Indexed keywords

BLEOMYCIN; CALRETICULIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEMBRANE; CLINICAL ARTICLE; DERMIS; ELECTROCHEMOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; METASTATIC MELANOMA; MIDDLE AGED; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; SKIN BIOPSY; SKIN METASTASIS; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; VERY ELDERLY; CD4+ T LYMPHOCYTE; GENETICS; IMMUNOLOGY; MELANOMA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY;

AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; ELECTROCHEMOTHERAPY; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 84980043230     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-016-9814-x     Document Type: Article

References (47)

1. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavcic D, Pavlovic I et al (2006) Electrochemotherapy—an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4:3–13
2. Möller MG, Salwa S, Soden DM, O’Sullivan GC (2009) Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 9:1611–1630
3. Cadossi R, Ronchetti M, Cadossi M (2014) Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol 10:877–890
4. Mir LM (2006) Basis and rationale of the electrochemotherapy. Eur J Cancer Suppl 4:38–44
5. Mir LM, Gehl J, Sersa G, Collins CG, Garbay J-R, Billard V, Geertsen PF, Rudolf Z, O’Sullivan GC, Marty M (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the cliniporator by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 4:14–25
6. Caracò C, Mozzillo N, Marone U, Simeone E, Benedetto L, Di Monta G, Di Cecilia ML, Botti G, Ascierto PA (2013) Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer 13:564–568
7. Campana LG, Testori A, Mozzillo N, Rossi CR (2014) Treatment of metastatic melanoma with electochemotherapy. J Surg Oncol 109:301–307
8. Queirolo P, Marincola F, Spagnolo F (2014) Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. Arch Dermatol Res 306:521–526
9. Ricotti F, Giuliodori K, Cataldi I, Campanati A, Ganzetti G, Ricotti G, Offidani A (2014) Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther 27:148–152
10. Mekid H, Tounekti O, Spatz A, Cemazar M, El Kebir FZ, Mir LM (2003) In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Br J Cancer 88:1763–1771
11. Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, Zitvogel L, Mir LM, Robert C (2008) Tumour destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumour responses. Cancer Immunol Immunother 57:1291–1300
12. Calvet CY, Famin D, André FM, Mir LM (2014) Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 3:e28131
13. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N et al (2014) Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3:e955691
14. Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72
15. Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L (2013) Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 30:37–45
16. Gerlini G, Di Gennaro P, Borgognoni L (2012) Enhancing antimelanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 1:1655–1657
17. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570
18. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13:e32–e42
19. Whiteside TL, Schuler P, Schilling B (2012) Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 12:1383–1397
20. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R et al (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203:1693–1700
21. + T reg cells. J Exp Med 203:1701–1711
22. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759–767
23. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, Madeo F, Kroemer G (2008) The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15:1499–1509
24. Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F (2014) Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol 109:270–274
25. Quaglino P, Osella-Abate S, Marenco F, Nardo T, Gado C, Novelli M, Savoia P, Bernengo MG (2011) FoxP3 expression on melanoma cells is related to early visceral spreading in melanoma patients treated by electrochemotherapy. Pigment Cell Melanoma Res 24:734–736
26. Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, Thor Straten P (2003) Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13:449–459
27. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumour antigens recognized by T cells. Cancer Immunol Immunother 50:3–15
28. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Liénard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641–1650
29. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 24:1966–1973
30. + T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 63:2345–2535
31. Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother 29:233–240
32. Gerlini G, Tun-Kuy A, Dudli C, Burg G, Pimpinelli N, Nestle FO (2004) Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumour lesions. Am J Pathol 165:1853–1863
33. Stewart TJ, Abrams SI (2008) How tumours escape mass destruction. Oncogene 27:5894–5903
34. Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7–13
35. Pardoll DM (1998) Cancer vaccines. Nat Med 4:525–531
36. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA (2009) Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 21:281–285
37. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5:1219–1226
38. Charles J, Chaperot L, Salameire D, Di Domizio J, Aspord C, Gressin R, Jacob MC, Richard MJ, Beani JC, Plumas J et al (2010) Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol 20:16–23
39. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, Shepherd D, Colonna M, Cerundolo V (2003) Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 33:1052–1062
40. Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, Kissenpfennig A, Hermans IF, Ronchese F (2008) Tumour immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 180:1991–1998
41. + T cell-derived licensing factor for dendritic cell activation. J Immunol 184:4625–4629
42. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G et al (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:1089–1096
43. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155–164
44. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
45. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704
46. Srivastava N, McDermott D (2014) Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res 6:279–289
47. Calvet CY, Mir LM (2016) The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev 35:165–177